Results 21 to 30 of about 471,570 (210)

A case of localized bullous scleroderma

open access: yesVestnik Dermatologii i Venerologii, 2017
Bullous scleroderma is a rare type of the focal form of the disease mainly affecting the skin and characterized by induration and sclerosis foci as well as subepidermal blisters containing a transparent matter.
A. L. Bakulev   +3 more
doaj   +2 more sources

A Patient with Localized Scleroderma Successfully Treated with Etretinate

open access: yesCase Reports in Dermatology, 2014
There are several treatment methods for localized scleroderma, but treatment is difficult when the lesion is widely distributed. We encountered a case who was treated successfully with etretinate, a vitamin A derivative.
Tomoko Shima   +3 more
doaj   +2 more sources

Synthetic Nucleic Acid Antigens in Localized Scleroderma [PDF]

open access: yes, 2023
We investigated the impact of synthetic nucleic acid antigens on the autoantibody profiles in patients with localized scleroderma, an autoimmune skin disease. Anti-DNA antibodies, including double-stranded DNA (dsDNA) and single-stranded DNA (ssDNA), are
Torok, Kathryn S.   +16 more
core   +1 more source

Hand disease in scleroderma: a clinical correlate for chronic hand transplant rejection [PDF]

open access: yes, 2013
Chronic rejection remains a potential long-term consequence of hand composite tissue allotransplantation (CTA). Scleroderma has already been proposed as a model for chronic facial allograft rejection based on potential parallels of observed progression ...
Puri, A   +6 more
core   +1 more source

Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients [PDF]

open access: yes, 2001
Patients with scleroderma receiving Iloprost as a treatment for severe Raynaud's phenomenon report a reduction in skin tightness, suggesting that this drug inhibits skin fibrosis.
Stratton, R   +17 more
core   +1 more source

Association between Localized Scleroderma Cutaneous Assessment Tool and clinicopathologic characteristics in patients with morphea

open access: yesTurkderm Turkish Archives of Dermatology and Venereology, 2022
Background and Design: Morphea is also known as localized scleroderma. It is a rare autoimmune skin disease characterized by inflammation and sclerosis in the dermis and sometimes in the subcutaneous tissue.
Yıldız Gürsel Ürün   +1 more
doaj   +1 more source

Antinuclear Antibodies in Localized Scleroderma [PDF]

open access: yesArthritis & Rheumatism, 1983
AbstractWhen HeLa cells were used as the substrate for detection by the indirect immunofluorescence method, antinuclear antibodies were demonstrated in 16 of 22 (72.7%) sera from patients with localized scleroderma. When mouse kidney sections were used, the positive rate for antinuclear antibodies was 50% (11 of 22).
K, Takehara   +3 more
openaire   +3 more sources

A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis. [PDF]

open access: yes, 2015
In scleroderma (systemic sclerosis, SSc), persistent activation of myofibroblast leads to severe skin and organ fibrosis resistant to therapy. Increased mechanical stiffness in the involved fibrotic tissues is a hallmark clinical feature and a cause of ...
Ayuko Takahashi (789901)   +35 more
core   +1 more source

Renal perfusion in scleroderma patients assessed by microbubble-based contrast-enhanced ultrasound [PDF]

open access: yes, 2012
OBJECTIVES: Renal damage is common in scleroderma. It can occur acutely or chronically. Renal reserve might already be impaired before it can be detected by laboratory findings.
Himsel, Andrea   +12 more
core   +1 more source

Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma [PDF]

open access: yes, 2021
Objectives: To investigate safety and efficacy of MMF in patients with severe or MTX-refractory juvenile localized scleroderma. Methods: Consecutive juvenile localized scleroderma patients undergoing systemic treatment were included in a retrospective ...
Martini G.   +5 more
core   +3 more sources

Home - About - Disclaimer - Privacy